
    
      A phase IIa, single center, prospective, randomized, parallel, two-arms, single-dose,
      open-label with blinded assessor pilot clinical trial to assess ex vivo expanded adult
      autologous mesenchymal stromal cells fixed in allogeneic bone tissue (XCEL-MT-OSTEO-ALPHA) in
      non hypertrophic pseudoarthrosis of long bones.
    
  